Timothy M. Mayleben - Dec 17, 2021 Form 4 Insider Report for Landos Biopharma, Inc. (LABP)

Role: Interim CEO, Director
Signature: /s/ Eric W. Blanchard, attorney-in-fact
Stock symbol: LABP
Transactions as of: Dec 17, 2021
Transactions value $: $0
Form type: 4
Date filed: 12/21/2021, 03:21 PM
Previous filing: May 17, 2021
Next filing: Feb 7, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LABP	Stock Option (right to buy)	Award	$0	+253K		$0.00	253K	Dec 17, 2021	Common Stock	253K	$4.95	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this option vest in nine equal monthly installments from the vesting commencement date, subject to the Reporting Person's continuous service with the issuer at each vesting date. If the Reporting Person's employment is terminated prior to February 15, 2022 in connection with the employment of a regular Chief Executive Officer approved by the issuer's board of directors, then 190,113 of the unvested shares underlying the option will become fully vested on the termination date and the remaining shares will be forfeited. If the Reporting Person's employment is terminated on or after February 15, 2022 in connection with the employment of a regular Chief Executive Officer approved by the issuer's board of directors, then all unvested shares underlying the option will become fully vested on the termination date.

Content

The shares underlying this option vest in nine equal monthly installments from the vesting commencement date, subject to the Reporting Person's continuous service with the issuer at each vesting date. If the Reporting Person's employment is terminated prior to February 15, 2022 in connection with the employment of a regular Chief Executive Officer approved by the issuer's board of directors, then 190,113 of the unvested shares underlying the option will become fully vested on the termination date and the remaining shares will be forfeited. If the Reporting Person's employment is terminated on or after February 15, 2022 in connection with the employment of a regular Chief Executive Officer approved by the issuer's board of directors, then all unvested shares underlying the option will become fully vested on the termination date.